US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CERo Therapeutics Holdings, Inc.

1.99

-0.3800-16.03%

Post-market: 2.030.0400+2.01%19:58 EDT

Volume:428.15K

Turnover:912.51K

Market Cap:2.40M

PE:-0.06

High:2.37

Open:2.31

Low:1.93

Close:2.37

52wk High:895.40

52wk Low:1.93

Shares:1.21M

Float Shares:1.15M

Volume Ratio:0.58

T/O Rate:37.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-35.0792

EPS(LYR):-434.4641

ROE:--

ROA:-156.89%

PB:-0.23

PE(LYR):0.00

Loading ...

Overview Company News Filings

CERo Therapeutics Holdings (CERO) Receives a Buy from Maxim Group

Cero Therapeutics Holdings Inc. Announces $7 Million Private Placement of Series E Convertible Preferred Stock

BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv

BUZZ-CERo climbs after blood cancer drug trial moves to next phase

Cero Therapeutics Completes First Cohort of Phase 1 Trial for CER-1236 in AML, Initiates Next Dose Escalation

Cero Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of Cer-1236 in Aml

THOMSON REUTERS

Cero Therapeutics Holdings Inc - Asserts It Is Not for Sale or Seeking Partnerships

THOMSON REUTERS

Cero Therapeutics ‘open’ to takeover bids, Axios reports

CERo Therapeutics Advances Phase 1 Clinical Trial for CER-1236 in AML with Third Patient Dosed in Initial Cohort

Cero Therapeutics Progresses Phase 1 Cer-1236 Aml Trial With Dosing of Third Patient in Initial Dose Cohort

THOMSON REUTERS

CERo Therapeutics Is Maintained at Buy by D. Boral Capital

CERo Therapeutics Secures Notice of Allowance for U.S. Patent on CER-1236, Enhancing Cancer Treatment Protection Through 2041

BRIEF-CERo Therapeutics Advances Phase 1 CER-1236 Trial with Dose Intensification in AML

CERo Therapeutics Initiates Dose Intensification in Phase 1 Trial of CER-1236 for Acute Myeloid Leukemia

BUZZ-CERo Therapeutics jumps on US FDA's 'fast track' tag for cancer therapy

CERo Therapeutics Secures FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia, Enhancing Regulatory and Financial Pathways

Cero Therapeutics Receives FDA Fast Track Designation for Cer-1236 in Acute Myeloid Leukemia (Aml)

THOMSON REUTERS

Cero Therapeutics Holdings Inc. Faces Potential Nasdaq Delisting Due to Non-Compliance with Stockholders' Equity Requirement

CERo Therapeutics Hldgs Q2 EPS $(61.71) Misses $(11.21) Estimate

CERo Therapeutics Delays Q2 Financial Report Due to Valuation Finalization

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CERO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CERO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CERO\",,,,,undefined,":{"symbol":"CERO","market":"US","secType":"STK","nameCN":"CERo Therapeutics Holdings, Inc.","latestPrice":1.99,"timestamp":1760731200000,"preClose":2.37,"halted":0,"volume":428152,"hourTrading":{"tag":"盘后","latestPrice":2.03,"preClose":1.99,"latestTime":"19:58 EDT","volume":9366,"amount":18838.771,"timestamp":1760745516344},"delay":0,"floatShares":1152545,"shares":1205400,"eps":-35.07925,"marketStatus":"Market Closed","change":-0.38,"latestTime":"10-17 16:00:00 EDT","open":2.31,"high":2.37,"low":1.93,"amount":912512.9077552,"amplitude":0.185654,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-35.07925,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":2.37,"preHourTrading":{"tag":"盘前","latestPrice":2.32,"preClose":2.37,"latestTime":"09:28 EDT","volume":9688,"amount":23262.622152,"timestamp":1760707737598},"postHourTrading":{"tag":"盘后","latestPrice":2.03,"preClose":1.99,"latestTime":"19:58 EDT","volume":9366,"amount":18838.771,"timestamp":1760745516344},"volumeRatio":0.5830397835050823},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CERO\",,,,,undefined,":{"symbol":"CERO","floatShares":1152545,"roa":"-156.89%","roe":"--","lyrEps":-434.464112,"volumeRatio":0.5830397835050823,"shares":1205400,"dividePrice":0,"high":2.37,"amplitude":0.185654,"preClose":2.37,"low":1.93,"week52Low":1.93,"pbRate":"-0.23","week52High":895.4,"institutionHeld":0,"latestPrice":1.99,"eps":-35.07925,"divideRate":0,"volume":428152,"delay":0,"ttmEps":-35.07925,"open":2.31,"prevYearClose":120,"prevWeekClose":3.31,"prevMonthClose":5.09,"prevQuarterClose":5.09,"fiveDayClose":3.31,"twentyDayClose":5.4,"sixtyDayClose":7.42},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CERO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-06-13","symbol":"CERO","defaultRemindTime":1749821400000,"type":"split","dateTimestamp":1749787200000,"forFactor":20,"toFactor":1,"ratio":20},{"market":"US","date":"2025-01-08","symbol":"CERO","defaultRemindTime":1736346600000,"type":"split","dateTimestamp":1736312400000,"forFactor":100,"toFactor":1,"ratio":100},{"market":"US","date":"2024-02-15","symbol":"CERO","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CERO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CERO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1750824000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CERO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CERO","date":"2025-10-17","current":-0.056729,"percent":0.997494,"low":-23.40166,"twenty":-5.780711,"median":-0.966838,"eighty":-0.335444,"high":-0.137942,"avg":-3.271355,"sd":4.589801,"marketCap":2856802},"quantilePoints":[{"date":"2024-02-23","current":-14.247617,"twenty":-20.956561,"median":-17.613942,"eighty":-14.944588,"marketCap":35849112},{"date":"2024-03-01","current":-17.506812,"twenty":-18.431546,"median":-15.409236,"eighty":-15.153206,"marketCap":44049729},{"date":"2024-03-08","current":-18.247371,"twenty":-17.820809,"median":-15.409236,"eighty":-15.203159,"marketCap":45913085},{"date":"2024-03-15","current":-13.270815,"twenty":-17.820809,"median":-15.409236,"eighty":-15.057448,"marketCap":33391335},{"date":"2024-03-22","current":-12.856102,"twenty":-17.518661,"median":-15.34438,"eighty":-13.839564,"marketCap":32347855},{"date":"2024-03-28","current":-9.656887,"twenty":-17.423869,"median":-15.187199,"eighty":-12.785008,"marketCap":24298158},{"date":"2024-04-05","current":-11.26226,"twenty":-17.423869,"median":-15.107401,"eighty":-12.559878,"marketCap":28563716},{"date":"2024-04-12","current":-10.85589,"twenty":-17.252059,"median":-14.262796,"eighty":-11.529063,"marketCap":27533066},{"date":"2024-04-19","current":-8.940145,"twenty":-16.820909,"median":-13.270815,"eighty":-10.646899,"marketCap":22674290},{"date":"2024-04-26","current":-8.185457,"twenty":-16.072132,"median":-12.878911,"eighty":-10.171589,"marketCap":20760226},{"date":"2024-05-03","current":-8.011298,"twenty":-15.61915,"median":-12.441389,"eighty":-9.218799,"marketCap":20318519},{"date":"2024-05-10","current":-6.676082,"twenty":-15.409236,"median":-11.944081,"eighty":-8.208678,"marketCap":16932099},{"date":"2024-05-17","current":-6.559976,"twenty":-15.406992,"median":-11.26226,"eighty":-8.011298,"marketCap":16637628},{"date":"2024-05-24","current":-5.773123,"twenty":-15.356229,"median":-10.681731,"eighty":-7.83714,"marketCap":13841623},{"date":"2024-05-31","current":-6.030941,"twenty":-15.281507,"median":-10.409864,"eighty":-6.954736,"marketCap":14459767},{"date":"2024-06-07","current":-4.748738,"twenty":-15.235078,"median":-10.159255,"eighty":-6.68061,"marketCap":11385560},{"date":"2024-06-14","current":-2.25909,"twenty":-15.107401,"median":-9.656887,"eighty":-6.509425,"marketCap":5416387},{"date":"2024-06-21","current":-1.821847,"twenty":-15.007495,"median":-8.940145,"eighty":-6.069835,"marketCap":4368054},{"date":"2024-06-28","current":-1.912311,"twenty":-14.84161,"median":-8.707933,"eighty":-5.984352,"marketCap":4584951},{"date":"2024-07-05","current":-1.595686,"twenty":-14.277975,"median":-8.24351,"eighty":-5.773123,"marketCap":3825813},{"date":"2024-07-12","current":-1.228176,"twenty":-14.247617,"median":-8.069351,"eighty":-4.748738,"marketCap":2944671},{"date":"2024-07-15","current":-1.226291,"twenty":-14.24184,"median":-8.069351,"eighty":-4.719086,"marketCap":2940152},{"date":"2024-08-02","current":-1.013952,"twenty":-14.236062,"median":-8.040325,"eighty":-4.535268,"marketCap":2431048},{"date":"2024-08-09","current":-0.885794,"twenty":-13.839564,"median":-8.011298,"eighty":-2.310102,"marketCap":2123778},{"date":"2024-08-16","current":-0.654013,"twenty":-13.158247,"median":-7.83714,"eighty":-1.891957,"marketCap":2229214},{"date":"2024-08-23","current":-2.636712,"twenty":-12.954324,"median":-7.140505,"eighty":-1.844463,"marketCap":7260829},{"date":"2024-08-30","current":-2.420589,"twenty":-12.883473,"median":-6.744599,"eighty":-1.891957,"marketCap":6665683},{"date":"2024-09-06","current":-2.068131,"twenty":-12.832404,"median":-6.687402,"eighty":-1.924373,"marketCap":5695102},{"date":"2024-09-13","current":-1.60378,"twenty":-12.678367,"median":-6.559976,"eighty":-1.829704,"marketCap":4416400},{"date":"2024-09-20","current":-1.622429,"twenty":-12.393993,"median":-6.417311,"eighty":-1.725453,"marketCap":4467754},{"date":"2024-09-27","current":-1.758564,"twenty":-12.190139,"median":-6.030941,"eighty":-1.729099,"marketCap":4842634},{"date":"2024-10-04","current":-1.723131,"twenty":-12.057464,"median":-5.826769,"eighty":-1.723525,"marketCap":4745063},{"date":"2024-10-11","current":-1.770191,"twenty":-11.67976,"median":-5.685419,"eighty":-1.725453,"marketCap":4874653},{"date":"2024-10-18","current":-1.640939,"twenty":-11.355145,"median":-5.192459,"eighty":-1.725453,"marketCap":4518726},{"date":"2024-10-25","current":-4.541316,"twenty":-11.227428,"median":-4.704227,"eighty":-1.717164,"marketCap":12505622},{"date":"2024-10-31","current":-4.448525,"twenty":-11.088102,"median":-4.448525,"eighty":-1.723131,"marketCap":12250098},{"date":"2024-11-08","current":-3.853568,"twenty":-10.85589,"median":-4.424907,"eighty":-1.725101,"marketCap":10611741},{"date":"2024-11-15","current":-10.217961,"twenty":-11.088102,"median":-4.448525,"eighty":-1.726861,"marketCap":28137649},{"date":"2024-11-22","current":-5.605162,"twenty":-11.378366,"median":-4.622772,"eighty":-1.72898,"marketCap":37261342},{"date":"2024-11-29","current":-5.285991,"twenty":-11.285481,"median":-4.70795,"eighty":-1.736236,"marketCap":29010326},{"date":"2024-12-06","current":-5.244908,"twenty":-11.122934,"median":-4.743697,"eighty":-1.739542,"marketCap":28784857},{"date":"2024-12-13","current":-1.906243,"twenty":-10.902332,"median":-4.70795,"eighty":-1.744391,"marketCap":10461755},{"date":"2024-12-20","current":-1.478982,"twenty":-10.729812,"median":-4.535858,"eighty":-1.726509,"marketCap":8116878},{"date":"2024-12-27","current":-2.097767,"twenty":-10.58386,"median":-4.43215,"eighty":-1.724313,"marketCap":11512866},{"date":"2025-01-03","current":-2.13273,"twenty":-10.499069,"median":-4.417664,"eighty":-1.725805,"marketCap":11704747},{"date":"2025-01-10","current":-1.293623,"twenty":-10.455734,"median":-4.2029,"eighty":-1.723525,"marketCap":7099600},{"date":"2025-01-17","current":-0.870573,"twenty":-10.310323,"median":-4.062655,"eighty":-1.649339,"marketCap":4777839},{"date":"2025-01-24","current":-0.821625,"twenty":-10.217961,"median":-3.965464,"eighty":-1.627827,"marketCap":4509205},{"date":"2025-01-31","current":-0.695759,"twenty":-10.19009,"median":-3.820818,"eighty":-1.596315,"marketCap":3818433},{"date":"2025-02-07","current":-0.713241,"twenty":-10.159255,"median":-2.907717,"eighty":-1.573503,"marketCap":3914374},{"date":"2025-02-14","current":-0.62933,"twenty":-10.101202,"median":-2.636712,"eighty":-1.510537,"marketCap":3453859},{"date":"2025-02-21","current":-0.716737,"twenty":-9.74575,"median":-2.540899,"eighty":-1.377788,"marketCap":3933562},{"date":"2025-02-28","current":-0.562901,"twenty":-9.640801,"median":-2.437302,"eighty":-1.224909,"marketCap":3089285},{"date":"2025-03-07","current":-0.510457,"twenty":-9.079472,"median":-2.372103,"eighty":-1.030709,"marketCap":2801464},{"date":"2025-03-14","current":-0.335713,"twenty":-8.754375,"median":-2.239137,"eighty":-0.96912,"marketCap":1842442},{"date":"2025-03-21","current":-0.335643,"twenty":-8.503123,"median":-2.198781,"eighty":-0.896348,"marketCap":1842058},{"date":"2025-03-28","current":-0.267465,"twenty":-8.285192,"median":-2.14239,"eighty":-0.857987,"marketCap":1467890},{"date":"2025-04-04","current":-0.24439,"twenty":-8.197068,"median":-2.097767,"eighty":-0.804927,"marketCap":1341248},{"date":"2025-04-11","current":-0.269213,"twenty":-8.092572,"median":-2.074831,"eighty":-0.719534,"marketCap":1477484},{"date":"2025-04-17","current":-0.137942,"twenty":-8.069351,"median":-2.037496,"eighty":-0.697857,"marketCap":1145530},{"date":"2025-04-25","current":-0.719207,"twenty":-8.034519,"median":-1.993365,"eighty":-0.682473,"marketCap":5972602},{"date":"2025-05-02","current":-0.577828,"twenty":-8.011298,"median":-1.936658,"eighty":-0.655985,"marketCap":4798528},{"date":"2025-05-09","current":-0.472927,"twenty":-8.011298,"median":-1.906243,"eighty":-0.642767,"marketCap":3927389},{"date":"2025-05-16","current":-0.378199,"twenty":-7.976467,"median":-1.862996,"eighty":-0.625834,"marketCap":3140728},{"date":"2025-05-23","current":-0.254249,"twenty":-7.883582,"median":-1.835754,"eighty":-0.593155,"marketCap":2824879},{"date":"2025-05-30","current":-0.250375,"twenty":-7.83714,"median":-1.821847,"eighty":-0.577167,"marketCap":2781833},{"date":"2025-06-06","current":-0.207274,"twenty":-7.721034,"median":-1.77581,"eighty":-0.547912,"marketCap":2302949},{"date":"2025-06-13","current":-0.273488,"twenty":-7.384327,"median":-1.751459,"eighty":-0.512702,"marketCap":3038630},{"date":"2025-06-20","current":-0.399633,"twenty":-7.094063,"median":-1.745839,"eighty":-0.507659,"marketCap":4440184},{"date":"2025-06-27","current":-0.371137,"twenty":-6.877648,"median":-1.738983,"eighty":-0.492098,"marketCap":4123580},{"date":"2025-07-03","current":-0.321791,"twenty":-6.755064,"median":-1.72792,"eighty":-0.475494,"marketCap":3575313},{"date":"2025-07-11","current":-0.307543,"twenty":-6.734135,"median":-1.723131,"eighty":-0.413641,"marketCap":3417011},{"date":"2025-07-18","current":-0.302331,"twenty":-6.698722,"median":-1.689874,"eighty":-0.38886,"marketCap":3359096},{"date":"2025-07-25","current":-0.25785,"twenty":-6.676082,"median":-1.641077,"eighty":-0.371137,"marketCap":2864884},{"date":"2025-08-01","current":-0.269665,"twenty":-6.591905,"median":-1.625128,"eighty":-0.335643,"marketCap":2996159},{"date":"2025-08-08","current":-0.28148,"twenty":-6.559976,"median":-1.603475,"eighty":-0.331869,"marketCap":3127434},{"date":"2025-08-15","current":-0.879859,"twenty":-6.509425,"median":-1.595686,"eighty":-0.331869,"marketCap":9775810},{"date":"2025-08-22","current":-0.900472,"twenty":-6.509425,"median":-1.573503,"eighty":-0.332146,"marketCap":10004836},{"date":"2025-08-29","current":-0.656668,"twenty":-6.325196,"median":-1.544714,"eighty":-0.332216,"marketCap":9245433},{"date":"2025-09-05","current":-0.593312,"twenty":-6.128686,"median":-1.49476,"eighty":-0.334162,"marketCap":8353435},{"date":"2025-09-12","current":-0.470883,"twenty":-6.040664,"median":-1.396816,"eighty":-0.335444,"marketCap":6629711},{"date":"2025-09-19","current":-0.46489,"twenty":-5.984943,"median":-1.260899,"eighty":-0.335699,"marketCap":6545332},{"date":"2025-09-26","current":-0.460609,"twenty":-5.972853,"median":-1.219381,"eighty":-0.352439,"marketCap":6485062},{"date":"2025-10-03","current":-0.461465,"twenty":-5.86852,"median":-1.092587,"eighty":-0.368234,"marketCap":6497116},{"date":"2025-10-10","current":-0.367289,"twenty":-5.817345,"median":-0.98631,"eighty":-0.370367,"marketCap":5171174},{"date":"2025-10-17","current":-0.202908,"twenty":-5.780711,"median":-0.966838,"eighty":-0.335444,"marketCap":2856802}],"updateTime":1760809482906},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CERO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2575775531","title":"CERo Therapeutics Holdings (CERO) Receives a Buy from Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2575775531","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575775531?lang=en_us&edition=fundamental","pubTime":"2025-10-16 02:55","pubTimestamp":1760554530,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Jason McCarthy maintained a Buy rating on CERo Therapeutics Holdings yesterday. The company’s shares opened today at $2.87. McC...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cero-therapeutics-holdings-cero-receives-a-buy-from-maxim-group-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cero-therapeutics-holdings-cero-receives-a-buy-from-maxim-group-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2575215309","title":"Cero Therapeutics Holdings Inc. Announces $7 Million Private Placement of Series E Convertible Preferred Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2575215309","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575215309?lang=en_us&edition=fundamental","pubTime":"2025-10-14 21:12","pubTimestamp":1760447559,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. has announced a private placement, entering into a Securities Purchase Agreement with certain accredited investors for the sale of up to 9,750 shares of its Series E convertible preferred stock, raising up to $7 million in total. Approximately $1.8 million will be funded at the first closing, with additional closings subject to mutual agreement and customary conditions. As part of the agreement, holders of the company's outstanding Series C and Series D convertible preferred stock have consented to the issuance of the Series E shares on a pari passu basis, in exchange for a reduction in the conversion price of their shares to $1.76. The Series E preferred stock holders will also receive purchase rights if the company issues similar rights to common stockholders in the future.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL8Cbvkp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2575281804","title":"BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv","url":"https://stock-news.laohu8.com/highlight/detail?id=2575281804","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575281804?lang=en_us&edition=fundamental","pubTime":"2025-10-14 01:46","pubTimestamp":1760377569,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, VertivEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nL6N3VU0HC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNT","COP","LU0878866978.SGD","PGEN","ARDX","CERO","MKSI","NPO","LU1571399168.USD","NEM","LU2054465674.USD","ALK","SG9999014542.SGD","TGT","TVRD","AGX","BK4500","STX","BK4155","JEF","XOM","BK4566","SRRK","CVX","NDRA","SCCO","VRT","KDP","ABEO","FAST","MACW.SI","RNA","BCAX","LU0496367417.USD","DVN","BK4567","STUB"],"gpt_icon":1},{"id":"2575011364","title":"BUZZ-CERo climbs after blood cancer drug trial moves to next phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2575011364","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575011364?lang=en_us&edition=fundamental","pubTime":"2025-10-13 21:14","pubTimestamp":1760361247,"startTime":"0","endTime":"0","summary":"BUZZ-CERo climbs after blood cancer drug trial moves to next phase** U.S. drug developer CERo Therapeutics' CERO.O shares rise 7.2% to $3.55 in premarket trade** Co says its experimental drug for a type of blood drug, CER-1236 cleared a key safety milestone, allowing higher dosing in its ongoing clinical trial** CERO's CER-1236 is being tested in patients with acute myeloid leukemia, a fast-growing cancer of the blood and bone marrow** CERO says no serious side effects in initial patient group, clears path for higher dose** Safety panel clears start of second cohort with higher initial dose - CERO ** CERO says it is not for sale, correcting recent media report** Co says focus remains on dose escalation trial, not seeking partnerships** Up to last close, stock down ~97% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nL3N3VU0UF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2575406246","title":"Cero Therapeutics Completes First Cohort of Phase 1 Trial for CER-1236 in AML, Initiates Next Dose Escalation","url":"https://stock-news.laohu8.com/highlight/detail?id=2575406246","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575406246?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:30","pubTimestamp":1760358645,"startTime":"0","endTime":"0","summary":"CERo Therapeutics Holdings Inc. has announced the completion of the first cohort in its Phase 1 clinical trial of CER-1236, a cellular immunotherapy candidate for patients with acute myeloid leukemia . According to the company, no dose-limiting toxicities were observed in the initial cohort, and cell expansion consistent with preclinical expectations was reported. The completion of the first cohort allows the study to progress to the next planned dose level, pending regulatory approval. CERo Therapeutics stated that it is currently focused on advancing this dose-escalation trial and is not actively seeking acquisition or partnership opportunities at this time. Clinical results from the study have been collected to date; however, the company did not specify when further results will be presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL7fbG4k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR","BK4112","LU0314104364.USD","NDAQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2210150020.SGD","LU2095319765.USD","BK4139","BK4588"],"gpt_icon":0},{"id":"2575406468","title":"Cero Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of Cer-1236 in Aml","url":"https://stock-news.laohu8.com/highlight/detail?id=2575406468","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575406468?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:30","pubTimestamp":1760358600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nTUA7CGSRL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2575406404","title":"Cero Therapeutics Holdings Inc - Asserts It Is Not for Sale or Seeking Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=2575406404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575406404?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:30","pubTimestamp":1760358600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nTUA7CGSRL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2574376101","title":"Cero Therapeutics ‘open’ to takeover bids, Axios reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2574376101","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574376101?lang=en_us&edition=fundamental","pubTime":"2025-10-11 02:10","pubTimestamp":1760119820,"startTime":"0","endTime":"0","summary":"Cero Therapeutics (CERO), a T cell therapy biotech, is open to licensing deals or a sale as it awaits data on its lead asset, CEO Chris Ehrlich tel...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-open-to-takeover-bids-axios-reports-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cero-therapeutics-open-to-takeover-bids-axios-reports-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CERO","LENZ","BK4539","BK4139"],"gpt_icon":0},{"id":"2569787423","title":"CERo Therapeutics Advances Phase 1 Clinical Trial for CER-1236 in AML with Third Patient Dosed in Initial Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2569787423","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569787423?lang=en_us&edition=fundamental","pubTime":"2025-09-22 21:15","pubTimestamp":1758546913,"startTime":"0","endTime":"0","summary":"CERo Therapeutics Holdings Inc. has announced the progress of its Phase 1 clinical trial evaluating CER-1236 in acute myeloid leukemia . The company has successfully dosed the third patient in the initial dose cohort of the study. This marks the completion of the planned enrollment for the starting dose group, pending the outcome of safety assessments, including the dose-limiting toxicity evaluation period. The trial is designed to assess the safety, tolerability, and preliminary activity of CER-1236 in patients with various forms of AML. As the study continues, CERo plans to explore higher dosing levels to further investigate the potential for enhanced biological activity. Results from the study are anticipated to be presented in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDL3btgNm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU2210149790.SGD","BK4139","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","NDAQ","LU2095319765.USD","IE00B64PRP62.GBP","CERO","BK4588"],"gpt_icon":0},{"id":"2569126787","title":"Cero Therapeutics Progresses Phase 1 Cer-1236 Aml Trial With Dosing of Third Patient in Initial Dose Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2569126787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569126787?lang=en_us&edition=fundamental","pubTime":"2025-09-22 21:15","pubTimestamp":1758546900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nTUA8HGYNT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2566977666","title":"CERo Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2566977666","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566977666?lang=en_us&edition=fundamental","pubTime":"2025-09-09 20:51","pubTimestamp":1757422260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CERO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 09, 2025 08:51 ET (12:51 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CERO"],"gpt_icon":0},{"id":"2566692937","title":"CERo Therapeutics Secures Notice of Allowance for U.S. Patent on CER-1236, Enhancing Cancer Treatment Protection Through 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2566692937","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566692937?lang=en_us&edition=fundamental","pubTime":"2025-09-09 20:15","pubTimestamp":1757420115,"startTime":"0","endTime":"0","summary":"CERo Therapeutics Secures Notice of Allowance for U.S. Patent on CER-1236, Enhancing Cancer Treatment Protection Through 2041. CERo Therapeutics Holdings, Inc. recently announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its Application 19/019,111. This forthcoming patent will provide comprehensive protection for CER-1236, covering both the composition of matter and its use in treating cancer, with anticipated protection through 2041. Additionally, the company has been granted a patent by the Japanese patent office, resulting in a total of 20 granted patents and allowed applications for its compound and underlying technology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL9HV8zC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","CERO","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","NDAQ","IE00BKPKM429.USD","BK4139","LU2210149790.SGD","LU2095319765.USD","BK4588","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2565768480","title":"BRIEF-CERo Therapeutics Advances Phase 1 CER-1236 Trial with Dose Intensification in AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2565768480","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565768480?lang=en_us&edition=fundamental","pubTime":"2025-09-08 20:56","pubTimestamp":1757336185,"startTime":"0","endTime":"0","summary":"BRIEF-CERo Therapeutics Advances Phase 1 CER-1236 Trial with Dose Intensification in AMLSept 8 (Reuters) - CERo Therapeutics Holdings Inc CERO.O:CERO THERAPEUTICS ANNOUNCES DOSE INTENSIFICATION IN PHA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUA4RGRHQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2565681498","title":"CERo Therapeutics Initiates Dose Intensification in Phase 1 Trial of CER-1236 for Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2565681498","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565681498?lang=en_us&edition=fundamental","pubTime":"2025-09-08 20:45","pubTimestamp":1757335512,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. has announced an update in the Phase 1 clinical trial of its drug candidate CER-1236, targeting patients with acute myeloid leukemia . The company has intensified the dosing protocol for the study, administering a second dose to the second patient in the first cohort. This modification has been approved by the Institutional Review Board based on initial pharmacokinetic data indicating cell expansion. The aim is to assess the feasibility and safety of administering multiple infusions of CER-1236. The company plans to enroll a third patient in the cohort and anticipates that the protocol adjustment will yield valuable information regarding dosing, safety, and feasibility. Results from the trial have not yet been presented but are expected to provide insights as the study progresses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL3DwFcx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2095319765.USD","BK4112","BK4588","LU0314104364.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","BK4139","LU2210150020.SGD","CERO","LU2210149790.SGD"],"gpt_icon":0},{"id":"2565550085","title":"BUZZ-CERo Therapeutics jumps on US FDA's 'fast track' tag for cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2565550085","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565550085?lang=en_us&edition=fundamental","pubTime":"2025-09-05 20:16","pubTimestamp":1757074563,"startTime":"0","endTime":"0","summary":"BUZZ-CERo Therapeutics jumps on US FDA's 'fast track' tag for cancer therapy** Shares of drug developer CERo Therapeutics CERO.O rise 11% to $7.65 premarket** Co says its experimental blood cancer therapy, CER-1236, received U.S. FDA's \"fast track\" tag** FDA's \"fast track\" tag aims to speed development and review of drugs for serious conditions with unmet medical need** The therapy is being tested in an early stage trial for patients with aggressive forms of acute myeloid leukemia, a type of blood and bone marrow cancer** Stock down 94% YTD   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nL4N3US0TV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2565550920","title":"CERo Therapeutics Secures FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia, Enhancing Regulatory and Financial Pathways","url":"https://stock-news.laohu8.com/highlight/detail?id=2565550920","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565550920?lang=en_us&edition=fundamental","pubTime":"2025-09-05 20:00","pubTimestamp":1757073615,"startTime":"0","endTime":"0","summary":"CERo Therapeutics Secures FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia, Enhancing Regulatory and Financial Pathways. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on September 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL5Yzf1D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2095319765.USD","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR","LU2210150020.SGD","NDAQ","CERO","BK4588","IE00BKPKM429.USD","BK4585"],"gpt_icon":0},{"id":"2565550513","title":"Cero Therapeutics Receives FDA Fast Track Designation for Cer-1236 in Acute Myeloid Leukemia (Aml)","url":"https://stock-news.laohu8.com/highlight/detail?id=2565550513","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565550513?lang=en_us&edition=fundamental","pubTime":"2025-09-05 20:00","pubTimestamp":1757073600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nTUA38FS0T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2565300500","title":"Cero Therapeutics Holdings Inc. Faces Potential Nasdaq Delisting Due to Non-Compliance with Stockholders' Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2565300500","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565300500?lang=en_us&edition=fundamental","pubTime":"2025-09-05 04:14","pubTimestamp":1757016840,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc., a Delaware-based company, announced that it has received a notification from the Nasdaq Listing Qualifications department indicating non-compliance with the minimum stockholders' equity requirement of $2.5 million necessary for continued listing on the Nasdaq Capital Market. Previously out of compliance, the company had regained compliance in May 2025 but is now facing delisting as of September 8, 2025, due to the inability of Nasdaq staff to grant a cure period. In response, Cero Therapeutics has requested a hearing to appeal this determination, which will temporarily stay the suspension and delisting of its securities. The company plans to submit a compliance plan at the hearing, potentially involving public or private financing transactions, although no assurances can be made regarding the success of these efforts or the outcome of the appeal.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL99vxWg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2561283908","title":"CERo Therapeutics Hldgs Q2 EPS $(61.71) Misses $(11.21) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2561283908","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561283908?lang=en_us&edition=fundamental","pubTime":"2025-08-23 05:20","pubTimestamp":1755897600,"startTime":"0","endTime":"0","summary":"CERo Therapeutics Hldgs (NASDAQ:CERO) reported quarterly losses of $(61.71) per share which missed the analyst consensus estimate of $(11.21) by 450.74 percent. This is a 79.59 percent increase over losses of $(302.32)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47295105/cero-therapeutics-hldgs-q2-eps-61-71-misses-11-21-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","LENZ"],"gpt_icon":0},{"id":"2559468369","title":"CERo Therapeutics Delays Q2 Financial Report Due to Valuation Finalization","url":"https://stock-news.laohu8.com/highlight/detail?id=2559468369","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559468369?lang=en_us&edition=fundamental","pubTime":"2025-08-16 04:05","pubTimestamp":1755288356,"startTime":"0","endTime":"0","summary":"CERo Therapeutics Holdings, Inc., based in South San Francisco, has announced a delay in filing its Quarterly Report on Form 10-Q for the financial period ending June 30, 2025. The delay is attributed to the ongoing finalization of valuation and accounting treatment for marketable securities received as part of a securities purchase agreement. The company is working to resolve these issues as efficiently as possible.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 15, 2025, and is solely responsible for ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250815:nNDL6x4g80:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}]}}